%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
99 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-07T15:58:37Z
2024-03-28T04:55:24-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T04:55:24-07:00
application/pdf
Heather
2002-520.dec
uuid:fefcd69a-1dd1-11b2-0a00-ec0927edca00
uuid:fefcd69d-1dd1-11b2-0a00-380000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
117 0 obj
[121 0 R]
endobj
118 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0564 Tw 8 0 0 8 54 714.5293 Tm
(Groningen\), H. Lim \(Scheper Hospital, Emmen\), M. van Rijswijk and M.)Tj
0.0199 Tc 0.4556 Tw 0 -1.25 TD
[(van Leeuwen \(Academic Hospital, Groningen\), and F)79.9 (. Speerstra)]TJ
-0.00011 Tc 0.0849 Tw T*
[(\(W)39.7 (ilhelmina Hospital, )54.8 (Assen and Refaja Hospital, Stadskanaal\) from )17.7 (The)]TJ
0.0762 Tw T*
[(Netherlands; J. Pourel, I. Chary-V)110.7 (alckenaere \(Rheumatology Department,)]TJ
0.23689 Tw T*
[(University Hospital, Nancy\), S. Brian\215on and E. Le Bihan \(EA)-432.1 (3444,)]TJ
0.011 Tw T*
[(School of Public Health, Faculty of Medicine, Nancy\) in Lorraine, and J\
.P)110.8 (.)]TJ
0.01289 Tc 0.362 Tw T*
[(Eschard and F)79.7 (. Blanchard in Champagne-Ardenne, France; and S.)]TJ
-0.00011 Tc 0.3497 Tw T*
[(Odegaard \(Diakonhjemmet Hospital, Oslo\) in Norway)64.8 (, and all other)]TJ
0.0065 Tc 0.36839 Tw T*
[(rheumatologists for their collaboration. )17.7 (The authors are particularly)]TJ
-0.00011 Tc 0.02499 Tw T*
[(grateful to all patients for their cooperation in this study)64.8 (.)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 54 600.5293 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 590.7292 Tm
[(1.)-875.1 (V)110.8 (an der Heijde D, van Riel P)110.7 (, van Rijswijk M, van de Putte L.)]TJ
1.675 -1.225 Td
(Influence of prognostic features on the final outcome in rheumatoid)Tj
0 -1.225 TD
[(arthritis: a review of the literature. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(1988;17:284-92.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(2.)-875.1 (V)110.8 (an Zeben D, Hazes J, Zwinderman )54.8 (A, )17.7 (V)110.8 (andenbroucke J,)]TJ
1.675 -1.225 Td
[(Breedveld F)79.7 (. Factors predicting outcome of rheumatoid arthritis:)]TJ
T*
[(results of a followup study)64.8 (. J Rheumatol 1993;20:1288-96.)]TJ
-1.675 -1.2125 Td
[(3.)-875.1 (Uhlig )17.7 (T)74 (, Smedstad LM, )17.7 (V)110.8 (aglum P)110.7 (,)-0.1 ( Moum )17.7 (T)74 (, G\216rard N, Kvien )17.7 (T)74 (.)]TJ
1.675 -1.2125 Td
(The course of rheumatoid arthritis and predictors of psychological,)Tj
0 -1.2125 TD
(physical, and radiographic outcome after 5 years follow-up.)Tj
T*
(Rheumatology 2000;39:732-41.)Tj
-1.675 -1.2125 Td
[(4.)-875.1 (Plant MJ, Jones PW)91.7 (, Saklatvala J, Ollier )17.7 (W)91.8 (, Dawes P)110.7 (. Patterns of)]TJ
1.675 -1.2125 Td
(radiological progression in early rheumatoid arthritis: results of an)Tj
T*
[(8 year prospective study)64.8 (. J Rheumatol 1998;25:417-26.)]TJ
-1.675 -1.2125 Td
[(5.)-875.1 (W)79.9 (elsing PM, )17.7 (V)110.8 (an Gestel )54.8 (AM, Swinkels HL, Kiemeney LA, )17.7 (V)110.8 (an)]TJ
1.675 -1.2125 Td
[(Riel PL. )17.7 (The relationship between disease activity)64.9 (, joint )]TJ
T*
(destruction, and functional capacity over the course of rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 2001;44:2009-17.)]TJ
-1.675 -1.2125 Td
[(6.)-875.1 (Scott DJ. Prognostic factors in early rheumatoid arthritis.)]TJ
1.675 -1.2125 Td
(Rheumatology Oxford 2000;39 Suppl 1:24-9.)Tj
-1.675 -1.2125 Td
[(7.)-875.1 (V)110.8 (an der Heijde D, van Leeuwen M, van Riel P)110.7 (, van de Putte L.)]TJ
1.675 -1.2125 Td
(Radiographic progression on radiographs of hands and feet during)Tj
T*
(the first 3 years of rheumatoid arthritis measured according to)Tj
T*
[(Sharp\325)54.8 (s method \(van der Heijde modification\). J Rheumatol)]TJ
0 Tc 0 Tw T*
(1995;22:1792-6.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.2125 Td
[(8.)-875.1 (Smolen JS, Kalden JR, Scott DJ, et al. Ef)17.7 (ficacy and safety of)]TJ
1.675 -1.2125 Td
(leflunomide compared with placebo and sulphasalazine in active)Tj
T*
(rheumatoid arthritis: a double-blind randomised, multicentre trial.)Tj
T*
[(European Leflunomide Study)64.8 (. Lancet 1999;353:259-66.)]TJ
-1.675 -1.2125 Td
[(9.)-875.1 (Maini R, St. Clair EW)91.7 (, Breedveld F)79.7 (, et al. Infliximab \(chimeric)]TJ
1.675 -1.2125 Td
(anti-tumour necrosis factor alpha monoclonal antibody\) versus)Tj
T*
(placebo in rheumatoid arthritis patients receiving concomitant)Tj
T*
[(methotrexate: a randomised phase III trial. )54.8 (A)110.8 (TTRACT)-257.3 (Study)]TJ
T*
(Group. Lancet 1999;354:1932-9.)Tj
-2.175 -1.2125 Td
[(10.)-875.1 (V)110.8 (an der Heijde D. How to read radiographs according to the)]TJ
2.175 -1.2125 Td
(Sharp/van der Heijde method. J Rheumatol 1999;26:743-5.)Tj
-2.1381 -1.2125 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Blanchard F)79.7 (, Brian\215on S, Guillemin F)79.7 (, et al. European research on)]TJ
2.1381 -1.2125 Td
(incapacitating diseases and social support. Int J Health Sci)Tj
0 Tc 0 Tw T*
(1990;1:217-28.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2125 Td
[(12.)-875.1 (Smedstad LM, Moum )17.7 (T)74 (, Guillemin F)79.7 (, et al. Correlates of functional)]TJ
2.175 -1.2125 Td
(disability in early rheumatoid arthritis: a cross-sectional study of)Tj
T*
(706 patients in four European countries. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1996;35:746-51.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2125 Td
[(13.)-875.1 (Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an)]TJ
2.175 -1.2125 Td
(articular index for the assessment of joint tenderness in patients)Tj
T*
(with rheumatoid arthritis. Q J Med 1968;37:393-406.)Tj
-2.175 -1.2125 Td
[(14.)-875.1 (V)110.8 (an der Heijde D, van Riel PL, Nuver)19.7 (-Zwart IH, Gribnau FW)91.7 (, van)]TJ
2.175 -1.2125 Td
[(de Putte L. Ef)17.7 (fects of hydroxychloroquine and sulphasalazine on)]TJ
T*
(progression of joint damage in rheumatoid arthritis. Lancet)Tj
0 Tc 0 Tw T*
(1989;1:1036-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2125 Td
[(15.)-875.1 (V)110.8 (an Leeuwen M, van Rijswijk M, Sluiter )17.7 (W)91.9 (, et al. Individual )]TJ
2.175 -1.2125 Td
(relationship between progression of radiological damage and the)Tj
T*
[(acute phase response in early rheumatoid arthritis. )17.7 (T)69.9 (owards )]TJ
T*
(development of a decision support system. J Rheumatol)Tj
0 Tc 0 Tw 33 79.8125 Td
(1997;24:20-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(16.)-875.1 (Boini S, Guillemin F)79.7 (. Radiographic scoring methods as outcome)]TJ
2.175 -1.225 Td
[(measures in rheumatoid arthritis: properties and advantages. )54.8 (Ann)]TJ
0 Tc 0 -1.225 TD
(Rheum Dis 2001;60:817-27.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(17.)-875.1 (Guillemin F)79.7 (, Oedegaard S, G\216rard N, Billot L, Boini S, Kvien )17.7 (TK.)]TJ
2.175 -1.225 Td
(Reproducibility and sensitivity to change of 5 scoring methods for)Tj
T*
[(hand X-ray damage in rheumatoid arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tc T*
(2000;59 Suppl 1:214.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(18.)-875.1 (V)110.8 (an der Heijde D, Boonen )54.8 (A, Boers M, Kostense P)110.7 (, van der Linden)]TJ
2.175 -1.225 Td
[(S. Reading radiographs in chronological order)39.7 (, in pairs or as single)]TJ
T*
(films has important implications for the discriminative power of)Tj
T*
(rheumatoid arthritis clinical trials. Rheumatology Oxford)Tj
0 Tc 0 Tw T*
(1999;38:1213-20.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(19.)-875.1 (V)110.8 (an der Heijde D, van Riel P)110.7 (, van Leeuwen M, van\325)17.7 (t Hof M, van)]TJ
2.175 -1.225 Td
(Rijswijk M, van de Putte L. Prognostic factors for radiographic)Tj
T*
[(damage and physical disability in early rheumatoid arthritis. )54.8 (A)]TJ
T*
(prospective follow-up study of 147 patients. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1992;31:519-25.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(20.)-875.1 (Brennan P)110.7 (, Harrison B, Barrett E, et al. )54.8 (A)-220.1 (simple algorithm to)]TJ
2.175 -1.225 Td
(predict the development of radiological erosions in patients with)Tj
T*
[(early rheumatoid arthritis: prospective cohort study)64.8 (. BMJ)]TJ
0 Tc 0 Tw T*
(1996;313:471-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(21.)-875.1 (Hulsmans HM, Jacobs JW)91.7 (, van der Heijde DM, van )]TJ
2.175 -1.225 Td
[(Albada-Kuipers GA, Schenk )36.8 (Y)128.9 (, Bijlsma JW)91.7 (. )17.7 (The course of )]TJ
T*
(radiologic damage during the first six years of rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 2000;43:1927-40.)Tj
-2.175 -1.225 Td
[(22.)-875.1 (Luukkainen R, Kaarela K, Isomaki H, et al. )17.7 (The prediction of )]TJ
2.175 -1.225 Td
(radiological destruction during the early stage of rheumatoid)Tj
T*
(arthritis. Clin Exp Rheumatol 1983;1:295-8.)Tj
-2.175 -1.225 Td
[(23.)-875.1 (Kaarela K. Prognostic factors and diagnostic criteria in early)]TJ
2.175 -1.225 Td
(rheumatoid arthritis. Scand J Rheumatol 1985;57:1-54.)Tj
-2.175 -1.225 Td
[(24.)-875.1 (Mottonen )17.7 (TT)73.9 (. Prediction of erosiveness and rate of development of)]TJ
2.175 -1.225 Td
[(new erosions in early rheumatoid arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1988;47:648-53.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(25.)-875.1 (Coste J, Spira )54.8 (A, Clerc D, Paolaggi JB. Prediction of articular)]TJ
2.175 -1.225 Td
(destruction in rheumatoid arthritis: disease activity markers )Tj
T*
(revisited. J Rheumatol 1997;24:28-34.)Tj
-2.175 -1.225 Td
[(26.)-875.1 (W)79.9 (olfe F)79.7 (, Sharp JT)73.9 (. Radiographic outcome of recent-onset )]TJ
2.175 -1.225 Td
[(rheumatoid arthritis. )54.8 (A)-220.1 (19-year study of radiographic progression.)]TJ
T*
(Arthritis Rheum 1998;41:1571-82.)Tj
-2.175 -1.225 Td
[(27.)-875.1 (Eberhardt K, )17.7 (Thorbjorn Jensen L, Horslev-Petersen K, Petterson H,)]TJ
2.175 -1.225 Td
[(Lorenzen I, )17.7 (W)79.9 (ollheim F)79.7 (. Serum aminoterminal type III procollagen)]TJ
T*
(peptide in early rheumatoid arthritis: relation to disease activity and)Tj
T*
(progression of joint damage. Clin Exp Rheumatol 1990;8:335-40.)Tj
-2.175 -1.225 Td
[(28.)-875.1 (Janson LM, )17.7 (V)110.8 (an der Horst-Bruinsma IE, )17.7 (V)110.8 (an Schaardenbur)17.7 (g D,)]TJ
2.175 -1.225 Td
(Bezemer PD, Dijkmans BA. Predictors of radiographic joint)Tj
T*
[(damage in patients with early rheumatoid arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2001;60:924-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(29.)-875.1 (Y)99.8 (oung )54.8 (A, Corbett M, )17.7 (W)39.8 (infield J, et al. )54.8 (A)-220.1 (prognosis index for)]TJ
2.175 -1.225 Td
(erosive changes in the hands, feet, and cervical spines in early)Tj
T*
(rheumatoid arthritis. Br J Rheumatol 1988;27:94-101.)Tj
-2.175 -1.225 Td
[(30.)-875.1 (van der Heide )54.8 (A, Remme CA, Hofman D, Jacobs J, Bijlsma J.)]TJ
2.175 -1.225 Td
(Prediction of progression of radiologic damage in newly diagnosed)Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:1466-74.)]TJ
-2.175 -1.225 Td
[(31.)-875.1 (Ludig )54.8 (A, Guillemin F)79.7 (, Chary-V)110.8 (alckenaere I, Suurmeijer )17.7 (TP)110.7 (, Moum)]TJ
2.175 -1.225 Td
[(T)74 (,)-0.1 ( van den Heuvel )17.7 (WJ. Drug consumption in the first years of)]TJ
T*
[(rheumatoid arthritis in France, )17.7 (The Netherlands, and Norway)64.8 (. )54.8 (A)]TJ
T*
(longitudinal study in the early nineties. Scand J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;29:352-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(32.)-875.1 (Combe B, Dougados M, Goupille P)110.7 (, et al. Prognostic factors for)]TJ
2.175 -1.225 Td
(radiographic damage in early rheumatoid arthritis: a multiparameter)Tj
T*
[(prospective study)64.9 (. )54.8 (Arthritis Rheum 2001;44:1736-43.)]TJ
-2.175 -1.225 Td
[(33.)-875.1 (Harrison B, )17.7 (Thomson )17.7 (W)91.8 (, Symmons D, et al. )17.7 (The influence of )]TJ
2.175 -1.225 Td
(HLA-DRB1 alleles and rheumatoid factor on disease outcome in an)Tj
T*
(inception cohort of patients with early inflammatory arthritis.)Tj
T*
(Arthritis Rheum 1999;42:2174-83.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Guillemin, et al: Pr)36.8 (ognostic factors for joint damage)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2589)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>stream
8;Z\6!H-pO%+G5@W:/NLYt3$''AEdH$s9a9C$S;(78\.+]Des?FkPs0m/QP;hS(Z#
>JEA6^:&3s'(,95@^Ro07,MtN0#GZ27M7s&^^Go:E(.qEjFU\@MhI6Rc5Jr9K#L@>
\,[d6b*Bt.(W&j-eCDVQd=MYHFGSQd_gRF(+KIYaN/.YU/AT7`k+pBk6m-Rn:n/*N
O?5uW'n)':aRN4?CbMuCaasj*1O#]>g!/*&M'W6"p;P<7d901o4V,TM&Zl&gb8d$c
!(r9>;)_YWd_;='iI!nS#kcCh(Ac;2l-`%L(5$KG`S1Qrun:RcO]?#q^In3(;7q8h)
7-fpq7U4B:Ge/F&9;C?1/&7LjRoBV3`5?#GC6e!rR5U6M??T-HRdFpDUnt"L)&'_b
kZBa#-eO/Mmda<)e`kb[Mc:rQBj.0&m:d$?qVumYf`nu0%[]h"0W'o?TluAd;(B4X
GtXg!#Tsct_:]Mo:t]AT!sA;"/CroN(I3T`@Ylm.aZjkg!'=^kdodibh3^1PctBFV.NAG
`b/\KOd*n[<\-sk@EI(5$aP1k)U#86[E#(?gM)Z.<`0W#M,=tte3B0P;8eJj39[8A
0pG:sHi$in1>V.B^Z3qOLA\EB1OJH5S^76O.F>B7p(mtN-Ip,KesC7]iBu7ak((WX
Pmeog8Ih[sN,Qa-Z"5e_.PXZa/&_G.Ac((05oq5a=.SdT4koh@4oO@*hZ3E'?nV~>
endstream
endobj
33 0 obj
[/Indexed/DeviceRGB 255 32 0 R]
endobj
32 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
59 0 obj
<>
endobj
13 0 obj
<>
endobj
52 0 obj
<>
endobj
88 0 obj
<>
endobj
104 0 obj
<>
endobj
53 0 obj
<>
endobj
80 0 obj
<>stream
HUiPSY1=5ˌQE[PtQQnDIXa ̈́} ,
6 226[cO5Ps^25uLM:U_:瞯ww10Cv.KDTM4Ab<:MssGD/,¯WY{wm7ߍA`tL-|M%oq;\CmL&JB$SJeRP!JPT]"Y=nbJ,B&LIÔ&N*"j6JL*>yf\("z߫}w/Y\+ &/c!1pXg0a>X&F;s0`[ǝ%!X&[4Igg\kVͪÜWes7̹e5[*:G]93\܋^˼
8弽XC wȍ<}NF$-\2(:gKr<$O6rN0(c'd0T4`0@J-KGGE*̔q6+!/VW1@B;Ί5s18@K |&ǯ}YRPjځ\3bGgښK5Zad-3X -#-hcU4Zyuņ}>Q3Zb_^pNY qe]ʺj>}1{Oh2!>/mg'Oo~S#"*4=U=g4l"nsˠ՚ך1zf5R>`d~`+ĢyU?zA6[l}?Ef)jȢ]UkQ禳y\ѽ'.)Qu<@ MeyRbg1[qrRYlx>A؏|cE
i=Y? TIpNm
fs5fOo\gk'[ぞ9CD\g6^y-n 57A&K27~:ߚ[ݲJ۽FuuҸ+BR?}Kw٦cW'oQHE[,BOrRsEla4G
>{akQan6WiQ͊MAVI`ƀ*RK hC;e=Q8cB)aC͇;~ػ(0G,.8lS& +/465mƧH\xWk4u@aE8JL9 Ai,xOhͦEɅ%oYCV]"9 n,r.]qW7tqXS
W!~7T`6lBXYZ:]mQgPWNE'Vn/\]EK+4 ZȆ
zHzFh5e{HF{ŭFKeWa}Q\"Ʀ+å9,c~CquZ 6LG{1Պn r"A2)VffH Lf+Z@7IkfVJ!-E2(zt]P0mduhc|ğ)'B;I'v7~ֹضUgbm'M}n2J'9輊^Rs)Q;s7QwTwgt>`m.@P{Q륬b(h>rBv{(s_6u~myo«<(;;3CE.ZoDEAsq9394=܇\(A`"Qd2_S)k{011aw}{{uŢ8?#xes-f_NxW`fqK-7fp2ok8 fp5A0lŰ,U߈]z$%JHAٮ KmDs]
t
pF1m-@*D=t2 FC⇤:w/!9<ǿi!wS<9ɚ+
')fs+l=dHhiXAq(LP:EA%{5=2)iм?mdōmVscLpC
1HdT:H/U@t<:!4]_+Cc`S}{aو/&Ehõ.gJ1AQh54> -#6@#T8gs!W!2jY*7B~FF #M
2YEaVL%XF[ef({f%J? v+kDN0q]\TEhݰ[i z!z&}*ff,L+DmV^ɻp>F2}^_Q$T{[Q$ճ"ļm"I
"!f>F) eq5ӚwiWo
LП9Bʌv.mDK1BXebbD{nDNIPP?o>g>n+3Ђ=Wb0$nKC^(⻡?jG-Gw9JT}<ދ!5z(9>k lf a
s4./4$~MըE&
:"Ьu [ DCx+.#dH}hTv(<ݶ_|-yk=C];ڐLlQ,+uU(ڶV><[r/9W}G#{p+ԧ-5B/O2e{yҐLpo[raMtN;Lu)M:6@=rM$|4a_Oc
bYHBLj##wr%BtTz w"nSg1\zh68&jFpXCHOGxsMm<}K7üJk,.Q Q9؍Æ݊:FShf_ePc2+D9pR }PIO0aé](EmM!5N2Y'cg p+̼2NCXf>1 f*YM-]xvT
T)hLQ}łG=ٚ\{RHKN&-H%M^n
`D$ޒV]LZ$Hd&(fAȅf7\ț"rJAѶb^#B\;t0.<ڴ9Y.?Pق_6Q(ZhĘtw5mŕ-]EH]0j)֊iBֹfIZf^j.BE-Tp:;?@&[ɺ28HO _e
'Y'Ku*
d'Qп䧂#oMһ%g{S[}j]]i,o(6()iBL+-V_a3)
Jܛb|_a<
Qүk4VTr
+J+cj
&c3&rj8!>v7!Z
#PA0+((>ۮ8[R|U|u?vgugܹ,1V@z]^K݆*/ʀާ-uM-Is yg$m*yF\R˂cϗ-eQxlZ]q65ѝUV/˦kaFAc,HTBxQHLyn$ܟ1NOzjۚSR2+e*ދ'ݝ?z0Õq#yp9SSouKJR'10٤}1¤HH[
̡̜'ϴ1֠6MUudQhx
A&H`?%;p: sy\'k>͘}u2(HX!S~1vi
E<w5~e
F|n5$ܘFulUBDӽÝ~ީ7 5ºw,箄ipnnz`DŽ} Gqc;@6>Zk~ru[V47^|k U